Skip to content

Integrated Exercise Program in Opioid Agonist Therapy Clinics

Integrated Exercise in Opioid Agonist Therapy Clinics: A Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05242848
Acronym
BAReAktiv
Enrollment
309
Registered
2022-02-16
Start date
2022-04-07
Completion date
2025-03-01
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-Related Disorders

Keywords

Opiate substitution Treatment, Exercise Therapy, Exercise, Substance-Related Disorders

Brief summary

Background: Drug use is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. Particular people with opioid dependence have high morbidity and reduced quality of life. A reduction in fitness level for people with substance use disorder reduces the general health and quality of life. Physical activity is recommended as an adjunctive treatment for people with substance use disorder. Due to its positive effects on health, quality of life and substance use. There is minimal evidence from well-controlled randomised trials among people receiving opioid agonist therapy. However, studies indicate that exercise could be promising in opioid agonist therapy. Study design: BAReAktiv is a multicentre randomised controlled trial. The study aims to recruit approximately 225 patients receiving opioid agonist therapy. Intervention: A 16-week group-based exercise intervention with workouts twice a week. The exercise program will consist of endurance and strength training. The intervention will be integrated into outpatient's clinics in Bergen and Stavanger, Norway. Study population: The target group will be patients over 18 years of age with severe opioid use disorder receiving OAT in outpatient clinics. Expected outcome: This study will inform the relative advantages and disadvantages of an integrated exercise program as an adjunctive treatment. Both physical and mental health outcomes are of interest. Further scale-up will be considered if the provided exercise program is safe and effective.

Detailed description

See below each section

Interventions

BEHAVIORALExercise intervention

The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.

Sponsors

Helse Stavanger HF
CollaboratorOTHER_GOV
Helse Vest
CollaboratorOTHER
University of Bergen
CollaboratorOTHER
Haukeland University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Blinding is regarded as difficult and infeasible. Patients will be informed of the follow-up they will receive, but not on other follow-up alternatives that are used or the exact hypotheses for the study. Outcomes assessor will be blinded.

Intervention model description

The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Receiving OAT from an included outpatient clinic with follow-up weekly * Low level of physical activity measured using IPAQ (assessed at screening) * Confirming interest in participating in physical activity intervention and providing informed consent (criteria specified) * Giving informed consent

Exclusion criteria

* Not able to participate in the intervention due to physical disabilities or severe mental disorders * Being imprisoned or in inpatient treatment settings

Design outcomes

Primary

MeasureTime frameDescription
Psychological distressMid of the intervention period 16 weeks after initiationThe primary outcome is psychological distress assessed with the Norwegian validated translation ten item version of Hopkins Symptom Checklist (SCL-10) in the mid of the intervention period 16 weeks after initiation (12-20). This will be evaluated with mean SCL-10 item score and compared between intervention and control arm.

Secondary

MeasureTime frameDescription
Physical functioningMid of the intervention period 16 weeks after initiationPhysical functioning assessed with 4-minutes step-test measuring numbers of steps climbed in period
Fatigue Symptom ScaleMid of the intervention period 16 weeks after initiationChanges in fatigue will be assessed with the Fatigue Symptom Scale (FSS-3, 0-18, higher is worse)
Biochemical indicator of inflammationMid of the intervention period 16 weeks after initiationBiochemical indicators of inflammation measured with C-reactive protein in serum
Health-related quality of lifeMid of the intervention period 16 weeks after initiationChanges in quality of life will be assessed with EuroQoL five dimensions (EQ-5D-5L, 0-100, higher is better)

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026